Impact of QT interval prolongation following antiarrhythmic drug therapy on left ventricular function

Future Cardiol. 2017 Jan;13(1):13-22. doi: 10.2217/fca-2016-0052. Epub 2016 Dec 19.

Abstract

Aim: We assessed whether antiarrhythmic drug-induced QT interval prolongation affects left ventricular function.

Methods: Study population included 54 patients with symptomatic recent onset atrial fibrillation spontaneously cardioverted to sinus rhythm. Electrocardiographic and echocardiographic studies were done before initiating and after achieving drug's steady state.

Results: Significantly prolonged corrected QT interval (QTc) was noticed following only sotalol and amiodarone. The corrected precontraction time increased after sotalol (p = 0.005) and amiodarone (p = 0.017), not propafenone (p = 0.139). Analysis results between ΔEF and ΔQTc, ΔEF and ΔQTc(p), ΔE/e' and ΔQTc, ΔE/e' and ΔQTc(p) for amiodarone group were (p = 0.66, p = 0.20, p = 0.66, p = 0.33), for sotalol (p = 0.36, p = 0.51, p = 0.44, p = 0.33) and for propafenone (p = 0.38, p = 0.12, p = 0.89, p = 0.61), respectively.

Conclusion: QT interval prolongation following antiarrhythmic therapy does not affect significantly left ventricular function.

Keywords: QT interval prolongation; antiarrhythmic drug therapy; left ventricular function.

MeSH terms

  • Aged
  • Amiodarone / pharmacology
  • Anti-Arrhythmia Agents / pharmacology*
  • Atrial Fibrillation / diagnostic imaging
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / physiopathology
  • Echocardiography
  • Electrocardiography
  • Female
  • Heart Rate / drug effects*
  • Heart Rate / physiology
  • Humans
  • Male
  • Propafenone / pharmacology
  • Sotalol / pharmacology
  • Ventricular Function, Left / drug effects*
  • Ventricular Function, Left / physiology

Substances

  • Anti-Arrhythmia Agents
  • Propafenone
  • Sotalol
  • Amiodarone